Spots Global Cancer Trial Database for lee011
Every month we try and update this database with for lee011 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | NCT03070301 | Neuroendocrine ... | LEE011 everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of LEE011 in Asian Patients | NCT01898845 | Advanced Solid ... | LEE011 | 18 Years - | Novartis | |
| A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | NCT03070301 | Neuroendocrine ... | LEE011 everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | NCT02159066 | Melanoma | LGX818 MEK162 LEE011 BGJ398 BKM120 INC280 | 18 Years - | Pfizer | |
| A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | NCT01543698 | Solid Tumors Ha... | LGX818 MEK162 LEE011 | 18 Years - | Pfizer | |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. | NCT01237236 | Advanced Solid ... Lymphomas | LEE011 | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | NCT03070301 | Neuroendocrine ... | LEE011 everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | NCT01872260 | Breast Cancer | LEE011 Letrozole BYL719 | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Ribociclib (LEE011) Rollover Study for Continued Access | NCT02934568 | Continued Acces... | LEE011 | - 80 Years | Novartis | |
| Ribociclib (LEE011) Rollover Study for Continued Access | NCT02934568 | Continued Acces... | LEE011 | - 80 Years | Novartis | |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | NCT02343172 | Liposarcoma | HDM201 LEE011 | 18 Years - | Novartis | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | NCT02703571 | Solid Tumors fo... Pancreatic Canc... Colorectal Canc... | ribociclib Trametinib | 18 Years - | Novartis | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT02571829 | Liposarcoma Soft Tissue Sar... | ribociclib | 18 Years - | Hadassah Medical Organization | |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. | NCT01237236 | Advanced Solid ... Lymphomas | LEE011 | 18 Years - | Novartis | |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT03096912 | Liposarcomas, D... Liposarcoma - W... Liposarcoma; Mi... Soft-Tissue Sar... | Ribociclib | 18 Years - | Assaf-Harofeh Medical Center | |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | NCT03671330 | Breast Cancer | Ribociclib Plac... Ribociclib NSAI: Letrozole... Letrozole Goserelin | 18 Years - 60 Years | Novartis | |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | NCT02703571 | Solid Tumors fo... Pancreatic Canc... Colorectal Canc... | ribociclib Trametinib | 18 Years - | Novartis | |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | NCT02343172 | Liposarcoma | HDM201 LEE011 | 18 Years - | Novartis | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck | NCT02429089 | Squamous Cell C... | LEE011 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | NCT03822468 | Breast Cancer | Ribociclib Anastrozole Letrozole Goserelin | 18 Years - | Novartis | |
| A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | NCT01781572 | Locally Advance... | LEE011 MEK162 | 18 Years - | Pfizer | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck | NCT02429089 | Squamous Cell C... | LEE011 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT02571829 | Liposarcoma Soft Tissue Sar... | ribociclib | 18 Years - | Hadassah Medical Organization | |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | NCT02343172 | Liposarcoma | HDM201 LEE011 | 18 Years - | Novartis | |
| Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | NCT02088684 | Breast Cancer | LEE011 BYL719 fulvestrant BKM120 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
